Odylia co-founder Luk Vandenberghe talks to Nature about bioengineered viruses and the Odylia (non)-business model.

Researcher and entrepreneur Luk Vandenberghe thinks he can transport genes into cells much more efficiently by improving the viral vectors that carry them. He also describes how Odylia can leverage these new technologies to bring therapies for ultra-rare disorders into the clinic.

Read the full Nature article here